4.4 Review

Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide

期刊

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
卷 110, 期 12, 页码 1328-1341

出版社

OXFORD UNIV PRESS INC
DOI: 10.1093/jnci/djy171

关键词

-

类别

资金

  1. Australian Government Research Training Program Scholarship
  2. National Health and Medical Research Council of Australia
  3. Patti Blow Research Fund in Ophthalmology
  4. National Eye Institute of the National Institutes of Health [K08EY022672]
  5. National Cancer Institute [R21CA191943]
  6. Ohio Lions Eye Research Foundation
  7. Dutch Cancer Society [UL2012-5489, 2014-6905]
  8. Italian Ministry of Health 5 x 1000 per la Ricerca Corrente to Ospedale Policlinico San Martino
  9. Helsinki University Hospital Research Funds [TYH2017218]
  10. Sigrid Juselius Foundation
  11. Finnish Cancer Foundation
  12. Eye and Tissue Bank Foundation
  13. Folkhalsan Research Foundation
  14. Evald and Hilda Nissi Foundation
  15. Paulo Foundation
  16. Mary and Georg C. Ehrnrooth Foundation
  17. National Institutes of Health [K24CA149202]
  18. Spanish Fondo de Investigaciones Sanitarias [PI15/00716, PI15/00956]
  19. CIBER de Enfermedades Raras of the Instituto de Salud Carlos III, Spain
  20. European Development Regional Fund A way to achieve Europe ERDF
  21. Catalan Government, Spain [AGAUR 2014SGR603, 2017SGR1134]
  22. European Commission [LSHC-CT-2006018702]
  23. European Commission
  24. National Cancer Institute (NCI) of the National Institutes of Health (NIH) [CA83115]
  25. Fundacio La Marato de TV3, Catalonia, Spain [201331-30]
  26. Fundacion Cientifica de la Asociacion Espanola Contra el Cancer, Spain [GCB15152978SOEN]
  27. CERCA Programme/Generalitat de Catalunya
  28. Instituto de Salud Carlos III, Spain [FI14/00231]
  29. National Institutes of Health, National Cancer Institute [CA175691]
  30. Collaborative Ophthalmic Research Rotterdam (1.1.1)
  31. Wealtheon
  32. Bontius Stichting
  33. LSBS
  34. Stiching Blinden Penning
  35. ANVVB
  36. Oogfonds
  37. Karolinska Institutet's foundation grants for eye research
  38. NIH/NCI Cancer Center Support Grant [P30 CA008748]
  39. COACYT PhD fellowship
  40. Wellcome Trust [204562/Z/16/Z]
  41. UNAM PAPIIT [200318]
  42. Wellcome Trust [204562/Z/16/Z] Funding Source: Wellcome Trust

向作者/读者索取更多资源

Background: The BRCA1-associated protein-1 (BAP1) tumor predisposition syndrome (BAP1-TPDS) is a hereditary tumor syndrome caused by germline pathogenic variants in BAP1 encoding a tumor suppressor associated with uveal melanoma, mesothelioma, cutaneous melanoma, renal cell carcinoma, and cutaneous BAP1-inactivated melanocytic tumors. However, the full spectrum of tumors associated with the syndrome is yet to be determined. Improved understanding of the BAP1-TPDS is crucial for appropriate clinical management of BAP1 germline variant carriers and their families, including genetic counseling and surveillance for new tumors. Methods: We collated germline variant status, tumor diagnoses, and information on BAP1 immunohistochemistry or loss of somatic heterozygosity on 106 published and 75 unpublished BAP1 germline variant-positive families worldwide to better characterize the genotypes and phenotypes associated with the BAP1-TPDS. Tumor spectrum and ages of onset were compared between missense and null variants. All statistical tests were two-sided. Results: The 181 families carried 140 unique BAP1 germline variants. The collated data confirmed the core tumor spectrum associated with the BAP1-TPDS and showed that some families carrying missense variants can exhibit this phenotype. A variety of noncore BAP1-TPDS-associated tumors were found in families of variant carriers. Median ages of onset of core tumor types were lower in null than missense variant carriers for all tumors combined (P<.001), mesothelioma (P<.001), cutaneous melanoma (P<.001), and nonmelanoma skin cancer (P<.001). Conclusions: This analysis substantially increases the number of pathogenic BAP1 germline variants and refines the phenotype. It highlights the need for a curated registry of germline variant carriers for proper assessment of the clinical phenotype of the BAP1-TPDS and pathogenicity of new variants, thus guiding management of patients and informing areas requiring further research.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据